Q² Solutions
Q² Solutions, a wholly-owned subsidiary of IQVIA (NYSE: IQV), is a global central laboratory and specialty biomarker services platform that supports pharmaceutical and biotech sponsors with central lab, clinical genomics, bioanalytical, biomarker, vaccine, and discovery sciences across all phases of drug development.
- Company typePrivate
- Founded2015
- HeadquartersDurham, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Q² Solutions does
Q² Solutions is a wholly-owned subsidiary of IQVIA (NYSE: IQV) that operates as a global central laboratory and specialty biomarker services platform supporting drug discovery and clinical development. The company serves pharmaceutical and biotech sponsors across all phases of drug development — from early-stage discovery through Phase IV clinical trials — with a horizontally integrated service portfolio spanning central laboratory services, clinical genomics, bioanalytical LC-MS testing (small and large molecules), biomarker services, vaccine laboratory services, and discovery sciences.
Its technology foundation rests on proprietary digital platforms including LabMatrix for clinical trial sample lifecycle management and Site Lab Navigator, an advanced e-Requisition solution launched in 2024 to streamline site workflows and improve data accuracy. The unit also offers AI-driven digital pathology capabilities developed through a strategic collaboration with OracleBio, integrating AI image analysis into pathology workflows to enhance clinical insights for sponsors.
Commercially, Q² Solutions operates an enterprise field-sales motion, engaging pharmaceutical and biotech sponsors directly through scientific and operational teams to negotiate contracted laboratory and biomarker services. Revenue is generated via project-based and contract-based service fees tied to study complexity, volume, and scope, with pricing undisclosed publicly. The business is distributed through IQVIA's global laboratory facilities and investigator site network, supporting large, multi-regional clinical trial programs across multiple therapeutic areas.
Q² Solutions firmographics
Firmographics- Name
- Q² Solutions
- Legal name
- Q² Solutions
- Website
- https://q2labsolutions.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Q² Solutions, a wholly-owned subsidiary of IQVIA (NYSE: IQV), is a global central laboratory and specialty biomarker services platform that supports pharmaceutical and biotech sponsors with central lab, clinical genomics, bioanalytical, biomarker, vaccine, and discovery sciences across all phases of drug development.
- Ownership category
- akta.pro rank
Q² Solutions industry classification
Industry- Product category
- Clinical Laboratory Services
- NAICS
- Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)
- akta.pro secondary industries
- Bioanalytical & PK/PD Sample Analysis (Trial Support) (HLAGAEAG), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Lab Analytics, Utilization Management & Operational Intelligence (HLACAMAK), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)
Keywords
Where Q² Solutions is headquartered
LocationHeadquarters
- HQ city
- Durham
- HQ country
- United States
- HQ region
- North America
Markets served
Q² Solutions business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Central Laboratory Services: Provides comprehensive central laboratory services to pharmaceutical and biotech sponsors conducting clinical trials. Revenue is generated through service contracts for specimen analysis, lab operations, and site support across global trial networks.
- Specialty Biomarker and Bioanalytical Services: Specialty services including biomarker services, bioanalytical LC-MS testing, and clinical genomics, typically billed per project or per test delivered as part of a sponsor's drug development program.
- Vaccine Laboratory Services: Specialized vaccine development support services including lab testing and biomarker analysis for vaccine programs.
- Discovery Sciences: Preclinical and discovery-stage laboratory services supporting early-stage drug discovery programs for sponsors.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Q² Solutions product offering
Product offeringCore offering
Q² Solutions (operating as IQVIA Laboratories) delivers global central laboratory and specialty biomarker services for drug discovery and development. The portfolio spans central lab services, clinical genomics, bioanalytical LC-MS testing for small and large molecules, biomarker services, vaccine laboratory services, and discovery sciences, supported by digital technologies including Site Lab Navigator (e-Requisition) and LabMatrix clinical trial sample management. Services are contracted by pharmaceutical and biotech sponsors and deployed across global investigator site networks.
Product overview
IQVIA Laboratories offers a comprehensive suite of central laboratory and specialty biomarker services for drug discovery and development. The portfolio includes central laboratory services, digital technologies (including Labmatrix for sample management), clinical genomics, discovery sciences, bioanalytical laboratories with LC-MS capabilities, biomarker services, and vaccine laboratory services. Site Lab Navigator provides advanced e-Requisition capabilities for streamlined clinical trial workflows. Together, these services deliver industry-leading science, operational excellence, and tailored solutions at each stage of drug discovery and development.
Differentiator
Problem solved
Functional benefit
Products and services
- Central Laboratory Services Comprehensive central laboratory services for clinical trials, providing standardized testing, biomarker analysis, and global sample management across investigator sites for pharmaceutical and biotechnology sponsors conducting Phase I–IV studies.
- Site Lab Navigator An advanced e-Requisition solution that streamlines clinical trial workflows and enhances data accuracy for sponsors and investigator sites, providing site and patient centricity support.
- Digital Technologies (LabMatrix) Next-generation digital lab technologies including sample management solutions such as LabMatrix for clinical trial sample tracking and management across the lifecycle of clinical studies.
- Clinical Genomics Laboratory Specialty genomic laboratory services providing comprehensive genomics testing and analysis for clinical development programs conducted by pharmaceutical and biotech sponsors.
- Discovery Sciences Early-stage research and discovery laboratory services supporting drug discovery and preclinical development activities for pharmaceutical and biotechnology sponsors.
- Bioanalytical Laboratories Bioanalytical laboratory services including small and large molecule LC-MS testing for pharmacokinetic and biomarker assessments supporting clinical development programs.
- Biomarker Services Specialty biomarker testing services utilizing LC-MS technology for small and large molecule biomarker analysis as part of clinical trial laboratory offerings.
- Vaccine Laboratory Services Specialized laboratory services supporting vaccine development including clinical trial testing and immunological analysis for vaccine programs.
Quantifiable outcome
- Timely and reliable outcomes for clinical programs across drug discovery and development stages
Companies that use Q² Solutions
Customer profileSegments1 record
Ideal customer profiles1 record
Q² Solutions technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
Q² Solutions partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- OracleBiocoreIQVIA Laboratories has entered into a strategic collaboration with OracleBio to advance AI-driven digital pathology. The partnership integrates OracleBio's advanced AI image analysis capabilities into IQVIA Laboratories' digital pathology workflows, enhancing clinical insights for pharmaceutical sponsors. This collaboration strengthens IQVIA Laboratories' digital pathology offerings and extends the reach of AI-powered image analysis to a broader client base.
Scale indicators2 records
Recent moves4 records
Expansion highlights5 records
Q² Solutions competitors and assessment
Company assessmentEmerging players
- Bio-Techne: Provides reagents, assays, and biomarker testing tools used in clinical trial lab workflows. Adjacent competitor in specialty biomarker services with growing clinical lab service capabilities.
Direct peers
- ICON plc: Global CRO with central lab and bioanalytical capabilities following the PRA Health Sciences merger. Competes head-to-head with Q² Solutions for large multi-site central lab contracts across all phases.
- Medpace: Mid-sized CRO offering central lab and bioanalytical services as part of its full-service clinical development model. Competes with Q² Solutions for biotech and mid-pharma sponsor lab contracts.
- Fortrea (formerly Labcorp Drug Development): Direct competitor in central laboratory, bioanalytical, and biomarker services for clinical trials after Labcorp's clinical development services spin-off. Most comparable standalone peer with similar global central lab footprint and sponsor customer base.
- Syneos Health: Clinical research organization with central lab and bioanalytical service offerings. Competes for sponsor lab contracts across Phase I–IV clinical trials, particularly in bioanalytical and specialty biomarker testing.
- WuXi AppTec: Global contract research organization providing bioanalytical, central lab, biomarker, and clinical trial services. Comparable end-to-end lab services model with significant presence in Asia and growing global share.
- Eurofins Scientific: Global bioanalytical, central lab, and clinical diagnostics testing services provider. Competes directly in bioanalytical LC-MS, biomarker, and central lab services for pharma and biotech sponsors.
Regional players
- SGS (Société Générale de Surveillance): Global testing, inspection, and certification company with a clinical research services arm offering central lab and bioanalytical services. Comparable contract lab services model, with stronger presence in Europe.
Broad incumbents
- Charles River Laboratories: Provides preclinical and clinical laboratory services including bioanalytical and biomarker capabilities. Less central lab exposure but a comparable contract research and specialty lab services model serving large pharma.
- Thermo Fisher Scientific (PPD): Diversified life sciences tools leader whose PPD clinical research services include central lab and bioanalytical offerings. Broader instrument and reagent portfolio provides different scale advantages but overlapping clinical lab services.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Q² Solutions social profiles
Digital presenceQ² Solutions financial estimates
Financial estimateRevenue estimate
Valuation estimate
Q² Solutions leadership team
Management profileNumber of profiles
Q² Solutions funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Q² Solutions M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Q² Solutions
What does Q² Solutions do?
Q² Solutions (operating as IQVIA Laboratories) delivers global central laboratory and specialty biomarker services for drug discovery and development. The portfolio spans central lab services, clinical genomics, bioanalytical LC-MS testing for small and large molecules, biomarker services, vaccine laboratory services, and discovery sciences, supported by digital technologies including Site Lab Navigator (e-Requisition) and LabMatrix clinical trial sample management. Services are contracted by pharmaceutical and biotech sponsors and deployed across global investigator site networks.
Is Q² Solutions a public or private company?
Q² Solutions is a private company. It is classified as corporate owned and is currently operating.
When was Q² Solutions founded?
Q² Solutions was founded in 2015. It employs 1,001 to 5,000 people.
Where is Q² Solutions based?
Q² Solutions is headquartered in Durham, United States, in the North America region.
How does Q² Solutions make money?
Four revenue lines are on record. Central Laboratory Services are the primary driver. The others are specialty Biomarker and Bioanalytical Services, vaccine Laboratory Services and discovery Sciences.
Who are Q² Solutions's main competitors?
Bio-Techne is listed as an emerging player. Direct peers are ICON plc, Medpace, Fortrea (formerly Labcorp Drug Development), Syneos Health, WuXi AppTec and Eurofins Scientific. SGS (Société Générale de Surveillance) is listed as a regional player. Broad incumbents are Charles River Laboratories and Thermo Fisher Scientific (PPD).
Does Q² Solutions have an API?
No public API is recorded for Q² Solutions.
What industry is Q² Solutions in?
Q² Solutions's product category is Clinical Laboratory Services. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAGAEAG, Bioanalytical & PK/PD Sample Analysis (Trial Support). Its NAICS code is 621511 and its SIC code is 8071.